Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

MAVYRET

GLECAPREVIR; PIBRENTASVIR

Standard Dose
50MG/PACKET;20MG/PACKET
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview MAVYRET is listed in Drugs@FDA under application 215110 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient GLECAPREVIR; PIBRENTASVIR Form and strength PELLETS;ORAL - 50MG/PACKET;20MG/PACKET Sponsor ABBVIE Submission history Latest submission status date: 2025-06-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview MAVYRET is listed in Drugs@FDA under application 215110 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient GLECAPREVIR; PIBRENTASVIR Form and strength PELLETS;ORAL - 50MG/PACKET;20MG/PACKET Sponsor ABBVIE Submission history Latest submission status date: 2025-06-10 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.
MAVYRET (GLECAPREVIR; PIBRENTASVIR) | Drug Monograph | MedicHelpline